# What is the situation on cervical cancer screening in Germany as an European example ?

WHO global strategy to eliminate cervical cancer

**Prof. Dr. Thomas Iftner** 19.03.2021





© UNIVERSITÄTSKLINIKUM TÜBINGEN.

#### **Cervical Cancer Screening Program** Status in Germany before 2020


#### opportunistic screening program since 1971

- all in private hands ObGyn , Cytology office based
- over screening of young women
- under screening of elderly women
- > Pap smears at yearly intervals starting at the age of 20
- > no population based call recall system
- > no clearly defined triage strategy
- > no Certified Colposcopy Centers till 2015
- ho Cancer Registry for whole Germany



### age-standardized incidence of Cervical Cancer


Germany compared to other European Countries






### **Cervical Cancer in Germany**

#### age standardized incidence and mortality rate in Germany





#### **Cervical Cancer Screening** attendance rate by age




age group




Altenhofen, L. Hochrechnung zur Akzeptanz von Gesundheitsuntersuchungen und Krebsfrüherkennungsuntersuchungen bei gesetzlich Versicherten. Berlin, Zentralinstitut für die kassenärztliche Versorgung in der Bundesrepublik Deutschland; 2005.

#### **Cervical Cancer in Germany** age-specific incidence rates in 2013/14



Krebs in Deutschland für 2013/2014. 11. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2017; 10.17886/rkipubl-2017-007

#### **HPV Infection and Detection**





#### **Evaluation of Human Papillomaviruses** IARC Monographs


	Group	HPV types	Comments
		Alpha HPV types	
	1	16	Most potent HPV type causes cancer at several sites, e.g. anogenital tract, oral cavity
	1	18,31,33,35,39,45,51,52,56,58,59	Sufficient evidence for cervical cancer
	2A	68	Limited evidence in humans for cervical cancer and strong mechanistic evidence
	2B	26,53, <mark>66</mark> ,67,70,73,82	Limited evidence in humans for cervical cancer
	2B	30,34,69,85,97	Classified by phylogenetic analogy
	3	6 and 11	Inadequate epidemiological evidence and lack of carcinogenic potential in mechanistic studies
		Beta HPV types	
	2B	5 and 8	Limited evidence for skin cancer in patients with epidermodysplasia verruciformis
	3	Other beta (and gamma) types	Further research needed

HR-types



#### **Prevention of Cervical Cancer in Europe**

HPV testing vs. cytology in Sweden, the Netherlands, England, Italy




Ronco G, Dillner J, Elfstrom, KM et al.; Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; doi.org/10.1016/s0140-6736(13)62218-7



#### **Prevention of Cervical Cancer in the United States**

HPV testing vs. cytology (every 3 yrs) or cotesting (cytology & HPV test; every 5 yrs)



1,011,092 Women, age 30 to 64 yrs 2003-2012



Gage JC, Schiffman M, Katki HA et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. Journal of the National Cancer Institute 2014; doi.org/10.1093/jnci/dju153


#### **Current Situation in Germany**

The G-BA has decided 2016 to introduce an organized cervical cancer screening in Germany (starting 01.01.2020, earliest evaluated after 6 yrs):

Women older than 35 are offered a co-testing with HPV test and cytology, every 3 yrs. Women younger than 35 are offered an annual cytology (Pap smear).

> Federal Joint Committee (G-BA) = highest decision-making body of the joint selfgovernance of physicians, dentists, hospitals and health insurance funds in Germany – issues directives


#### **German Screening program** early detection of cervical cancer (oKFE-RL)





## German Screening program

early detection of cervical cancer (oKFE-RL)






## HPV vaccine surveillance study

The <u>Wol</u>fsburg HP<u>V</u> epidemiological <u>study</u> (WOLVES)

2,326 young Women (age 20 to 26), year 1983/84, 1988/89, 1993/94

- $\circ$  annual screening
- HPV detection with HC2 test, genotyping by PCR (SPF-10, LiPA)






#### HPV vaccine surveillance study

The <u>Wol</u>fsburg HP<u>V</u> epidemiological <u>study</u> (WOLVES)

genotyping by PCR (SPF-10, LiPA)





Unpublished data (2010-2020) from WOLVES

year 88/89 n = 166, FU n = 202 year 93/94 n = 97

#### **Summary**

Germany changed in January 2020 from annual cytology screening into two age-dependent new screening algorithms:

- Women 35+ yrs: co-testing with cytology and HPV test every 3 yrs
- In case of positive findings women are sent to colposcopy within 3 months

HPV vaccine was introduced in 2007

- 2007: coverage of 50-60 % (dropped below 30 %);
- 2012: coverage of 39.5% in the target group of girls
- surveillance study (≈2000 young women) eradication of HPV6, 11, 16 and 18 in the youngest vaccinated group and a significant reduction in the non-vaccinated group
- since 2018 vaccination of boys is recommended



# Thank you for your attention

**Prof. Dr. Thomas Iftner** 19.03.2021







1

© UNIVERSITÄTSKLINIKUM TÜBINGEN.